In January, we added 112 citations in DIDB, including 63 in vitro (with 21 articles published in January 2025) and 49 in vivo articles (with 27 articles published in January 2025).
8 NDA/BLAs approved in 2024, including acoramidis (ATTRUBY), cosibelimab (UNLOXCYT), crinecerfont (CRENESSITY), ensartinib (ENSACOVE), iomeprol (IOMERVU), landiolol (RAPIBLYK), olezarsen (TRYNGOLZA), and zenocutuzuma (BIZENGRI) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.